Literature DB >> 15474114

Vioxx: an unequal partnership between safety and efficacy.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15474114     DOI： 10.1016/S0140-6736(04)17198-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Patients' interests: paramount in randomised trials.

Authors:  Tony Stevens; Roger Wilson
Journal:  BMJ       Date:  2005-01-01

2.  Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

Authors:  C J Hawkey; G M Hawkey; S Everitt; M M Skelly; W A Stack; D Gray
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 3.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Do selective cyclo-oxygenase-2 inhibitors have a future?

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.